BTK Inhibitor Options Expand for CLL/SLL

Area of Science:

• Oncology
• Hematology
• Clinical Trials

Background:

• Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are common B-cell malignancies.
• Ibrutinib, a first-generation Bruton's tyrosine kinase (BTK) inhibitor, has been a standard treatment.
• The need for more effective and safer therapies in relapsed/refractory settings persists.

Purpose of the Study:

• To compare the efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory CLL/SLL.

Main Methods:

• The ALPINE trial was a phase III, randomized study.
• Patients received either zanubrutinib or ibrutinib.
• Progression-free survival (PFS) and safety were key endpoints.

Main Results:

• Zanubrutinib demonstrated superior progression-free survival compared to ibrutinib.
• Zanubrutinib exhibited a more favorable safety profile with fewer adverse events.
• Higher rates of treatment discontinuation due to adverse events were observed with ibrutinib.

Conclusions:

• Zanubrutinib represents a superior treatment option over ibrutinib for relapsed/refractory CLL/SLL.
• The improved safety profile of zanubrutinib may enhance patient adherence and long-term outcomes.
• These findings support zanubrutinib as a new standard of care in this patient population.